"Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study

To assess the in‐market use of Saxenda (liraglutide 3.0 mg) and Victoza (liraglutide 1.2 mg/1.8 mg) according to approved indications and posology. Click to show full abstract

To assess the in‐market use of Saxenda (liraglutide 3.0 mg) and Victoza (liraglutide 1.2 mg/1.8 mg) according to approved indications and posology.

Keywords: investigating potential; non authorized; two different; potential non; use two; authorized use

Journal Title: Diabetes
Year Published: 2022

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended